Vascular dementia medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
- Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
- Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
- Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Disease Name
- 1 Stage 1 – Name of stage
- 1.1 Specific Organ system involved 1
- 1.1.1 Adult
- Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
- Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
- Preferred regimen (3): drug name 500 mg q12h for 14-21 days
- Alternative regimen (1): drug name 500 mg PO q6h for 7β10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14β21 days
- Alternative regimen (3): drug name 500 mg PO q6h for 14β21 days
- 1.1.2 Pediatric
- 1.1.2.1 (Specific population e.g. children < 8 years of age)
- Preferred regimen (1): drug name 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
- Preferred regimen (2): drug name 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
- Alternative regimen (1): drug name10 mg/kg PO q6h (maximum, 500 mg per day)
- Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
- Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
- 1.1.2.2 (Specific population e.g. ‘children < 8 years of age’)
- Preferred regimen (1): drug name 4 mg/kg/day PO q12hοΌmaximum, 100 mg per doseοΌ
- Alternative regimen (1): drug name 10 mg/kg PO q6h (maximum, 500 mg per day)
- Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
- Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
- 1.1.2.1 (Specific population e.g. children < 8 years of age)
- 1.1.1 Adult
- 1.2 Specific Organ system involved 2
- 1.1 Specific Organ system involved 1
- 2 Stage 2 – Name of stage
- 2.1 Specific Organ system involved 1
- Note (1):
- Note (2):
- Note (3):
- 2.1.1 Adult
- Parenteral regimen
- Oral regimen
- Preferred regimen (1): drug name 500 mg PO q8h for 14 (14β21) days
- Preferred regimen (2): drug name 100 mg PO q12h for 14 (14β21) days
- Preferred regimen (3): drug name 500 mg PO q12h for 14 (14β21) days
- Alternative regimen (1): drug name 500 mg PO q6h for 7β10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14β21 days
- Alternative regimen (3):drug name 500 mg PO q6h for 14β21 days
- 2.1.2 Pediatric
- Parenteral regimen
- Preferred regimen (1): drug name 50β75 mg/kg IV q24h for 14 (14β21) days (maximum, 2 g)
- Alternative regimen (1): drug name 150β200 mg/kg/day IV q6β8h for 14 (14β21) days (maximum, 6 g per day)
- Alternative regimen (2): Β drug name 200,000β400,000 U/kg/day IV q4h for 14 (14β21) days (maximum, 18β24 million U per day) ‘(Contraindications/specific instructions)’
- Oral regimen
- Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14β21) days (maximum, 500 mg per dose)
- Preferred regimen (2): drug name (for children aged β₯ 8 years) 4 mg/kg/day PO q12h for 14 (14β21) days (maximum, 100 mg per dose)
- Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14β21) days (maximum, 500 mg per dose)
- Alternative regimen (1): drug name 10 mg/kg PO q6h 7β10 days (maximum, 500 mg per day)
- Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14β21 days (maximum, 500 mg per dose)
- Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14β21 days (maximum,500 mg per dose)
- Parenteral regimen
- 2.2 ‘Other Organ system involved 2′
- Note (1):
- Note (2):
- Note (3):
- 2.2.1 Adult
- Parenteral regimen
- Oral regimen
- Preferred regimen (1): drug name 500 mg PO q8h for 14 (14β21) days
- Preferred regimen (2): drug name 100 mg PO q12h for 14 (14β21) days
- Preferred regimen (3): drug name 500 mg PO q12h for 14 (14β21) days
- Alternative regimen (1): drug name 500 mg PO q6h for 7β10 days
- Alternative regimen (2): drug name 500 mg PO q12h for 14β21 days
- Alternative regimen (3):drug name 500 mg PO q6h for 14β21 days
- 2.2.2 Pediatric
- Parenteral regimen
- Preferred regimen (1): drug name 50β75 mg/kg IV q24h for 14 (14β21) days (maximum, 2 g)
- Alternative regimen (1): drug name 150β200 mg/kg/day IV q6β8h for 14 (14β21) days (maximum, 6 g per day)
- Alternative regimen (2): Β drug name 200,000β400,000 U/kg/day IV q4h for 14 (14β21) days (maximum, 18β24 million U per day)
- Oral regimen
- Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14β21) days (maximum, 500 mg per dose)
- Preferred regimen (2): drug name 4 mg/kg/day PO q12h for 14 (14β21) days (maximum, 100 mg per dose)
- Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14β21) days (maximum, 500 mg per dose)
- Alternative regimen (1): drug name 10 mg/kg PO q6h 7β10 days (maximum, 500 mg per day)
- Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14β21 days (maximum, 500 mg per dose)
- Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14β21 days (maximum,500 mg per dose)
- Parenteral regimen
- 2.1 Specific Organ system involved 1
References
- β Dichgans M, Zietemann V (November 2012). “Prevention of vascular cognitive impairment”. Stroke. 43 (11): 3137β46. doi:10.1161/STROKEAHA.112.651778. PMIDΒ 22935401.
- β Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe CD (September 2013). “Long-term effects of secondary prevention on cognitive function in stroke patients”. Circulation. 128 (12): 1341β8. doi:10.1161/CIRCULATIONAHA.113.002236. PMIDΒ 23935013.
Β© 2026 MyEClinic β IFTM Institut fΓΌr Telematik in der Medizin GmbH
